We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Matinas Biopharma Holdings Inc (MTNB) USD0.001

Sell:$1.03 Buy:$1.09 Change: $0.005 (0.47%)
Market closed |  Prices as at close on 26 November 2021 | Switch to live prices |
Change: $0.005 (0.47%)
Market closed |  Prices as at close on 26 November 2021 | Switch to live prices |
Change: $0.005 (0.47%)
Market closed |  Prices as at close on 26 November 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Matinas BioPharma Holdings, Inc. is a biopharmaceutical company that is focused on improving the intracellular delivery of therapeutics through its paradigm-changing lipid nanocrystal (LNC) delivery platform. The Company is engaged in developing LYPDISO, as well as its LNC platform delivery technology and a pipeline of associated product candidates, including MAT2203 and MAT2501. Its LYPDISO is a mixture of multiple long-chain omega-3 fatty acids, primarily eicosapentanoic acid (EPA) and docosapentanoic acid (DPA) encapsulated in a delayed-release soft gelatin capsule. The Company's anti-infective product candidate, MAT 2203, is an application of its LNC platform delivery technology to a spectrum anti-fungal drug called amphotericin B. The Company's MAT2501 is an LNC formulation of the spectrum aminoglycoside antibiotic agent amikacin, which utilizes its LNC platform.

Contact details

1545 Route 206 South, Suite 302
United States
+1 (908) 4848805

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$235.71 million
Shares in issue:
216.25 million
New York Stock Exchange
United States
US dollar

Key personnel

  • Jerome Jabbour
    President, Chief Executive Officer, Director
  • Keith Kucinski
    Chief Financial Officer
  • Hui Liu
    Chief Technology Officer
  • Raphael Mannino
    Chief Scientific Officer
  • James Ferguson
    Chief Medical Officer
  • Theresa Matkovits
    Chief Development Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.